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The objective of the present review is to discuss if the yeast vacuole can be used as a target for attenuation of
Candida albicans virulence. Literature searches were made electronically using predetermined inclusion
criteria. The main searches were made through a systematic strategy in PubMed and authoritative journals in
microbiology. It appeared that C. albicans virulence may be reduced by inhibiting vacuolar proton-
translocating ATPase (V-ATPase) functions and acidification of the yeast vacuole by V-ATPase inhibitors, by
seeking the synergistic effect of antifungals and non-antifungals affecting yeast vacuolar functions, and by
inhibiting filament production  also regulated by the vacuole. Accordingly, we may impair C. albicans
virulence by inhibiting functions of its vacuole, which plays essential roles during colonization and invasion of
the host. Except for drugs where indications for clinical use can be redefined, such interventions may be closer
to theory than to reality at the moment. But since the yeast is so difficult to eradicate by antifungal treatment,
it could be rewarding to seek new strategies for reducing its virulence rather than trying to eradicate it
completely from the microbiota, which often turns out to be impossible.
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C
andida albicans is recognized as an opportunistic
yeast that becomes pathogenic when the host
defense deteriorates. Many of us have this yeast
in the oral cavity, gut, and genitalia as a commensal. As
people are living longer through improvements in stan-
dards of life, the risk of acquiring infection by Candida
increases due to predisposing factors associated with
aged individuals. We might be able to compete with its
pathogenicity if we could make the yeast less virulent.
Since Candida infections are often considered diseases of
the diseased, it may not be so realistic to remove the yeast
entirely from the microbiota. Actually, antifungal treat-
ment is very often followed by a relapse unless local and
general predisposing factors to infection have been
eliminated. Improvement of our host defense is another
alternative but not so easy to achieve. It should also be
realized that there are limited possibilities for treatment
of Candida infections. Available drugs are few and
resistance toward antimycotics is increasing. Antifungal
therapy is often hampered by toxicity, moderate response
rates, and substantial interpatient variation in serum drug
levels. This is worrisome because systemic Candida
infections, which are increasing, are often associated
with high morbidity and mortality. Actually, Candida
species are now one of the four most common causes
of bloodstream and cardiovascular infections in US
hospitals (1, 2), and bloodstream infections caused by
Candida have a mortality rate as high as 50% (1, 3).
So the question remains, can we impair the virulence of
C. albicans, and if that is the case, how can we do it?
C. albicans has a number of virulence factors (4). The
present review will focus on its vacuolar functions as
possible targets for attenuation of its virulence.
The yeast vacuole and its ATPase
The vacuole is an organelle in yeasts and plants that is
analogous to the mammalian lysosome (Fig. 1). It plays
an important role in a number of cellular functions such
as in response to stress, adaptation to new environments,
and cell differentiation (5). For the vacuole to function
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optimally, maintenance of an intravacuolar acidic pH is
required. This is maintained by the vacuolar proton-
translocating ATPase (V-ATPase). This enzyme hydro-
lyzes ATP for transport of protons from the cytosol into
organelles. Important vacuolar functions such as calcium
and metal homeostasis (6), cargo sorting and membrane
trafficking in endocytic and secretory pathways (7), and
drug resistance (8) require V-ATPase-mediated acidifica-
tion and membrane energization.
There are two subcomplexes in the V-ATPase enzyme:
the water soluble V1 and the membrane-embedded V0
(Fig. 1). While the V1 subcomplex forms the site of ATP
binding and hydrolysis, the integral membrane V0 sub-
complex arranges for transport of protons from the
cytosol to the vacuole lumen. There are 14 different
subunits in the yeast ATPase with relative molecular
masses from 9,000 to 100,000. Eight different subunits A,
B, (C), D, E, F, G, and H make up the V1 domain while
the V0 domain contains the six remaining subunits called
a, c, c?, cn, d, and e (10). The V0a subunit is the only
fungal V-ATPase subunit that is encoded by two iso-
forms, that is, VPH1 and STV1. The driving of protons
into the lumen causes an acidic intraluminal pH6.25.
This pH is necessary for optimal function of different
degrading enzymes and a membrane potential necessary
for secondary transport systems. Interference with the
V-ATPase function interrupts a variety of important cel-
lular processes and stress responses important for fungal
pathogenicity (5).
V-ATPase activity and ergosterol
Ergosterol is an important constituent of fungal mem-
branes. There seems to be a critical requirement for
ergosterol in V-ATPase function, and this requirement
may actually underlie the antifungal effect of azoles (11).
Thus, Saccharomyces cerevisiae mutants that do not
produce ergosterol have alkaline vacuoles and produce
the so-called vma phenotype (see later) (5, 11). The mutant
phenotypes are due to reduced ATP hydrolysis and proton
pumping inside the ATPase and not to improper assembly
of the ATPase at the vacuolar membrane because of lack
of ergosterol. In C. albicans, fluconazole-impaired vacuo-
lar acidification resulted in alkaline vacuoles, and note-
worthy, ergosterol feeding restored ATPase function and
growth of yeast cells (11). Accordingly, a new regulatory
pathway in ATPase function and also a new mechanism
of azole toxicity have been identified in C. albicans (11).
Fig. 1. Assembly and trafficking of the yeast V-ATPase. Possible steps in assembly and transport of Vph1p- and Stv1p-
containing V-ATPases are shown. Shading of different organelles indicates extent of acidification; the vacuole is most intensely
colored as the most acidic compartment in the yeast cell. The first compartment in the secretory pathway showing evidence of
acidification is the Golgi apparatus. Vph1p-containing V-ATPases are known to travel to the vacuole via the prevacuolar
compartment and are believed to reach this compartment via the early endosome, which is also likely to be somewhat acidic.
Stv1p-containing V-ATPases appear to cycle between the prevacuolar compartment and the vacuole, and may also travel
through the early endosome. The RAVE complex assists in reassembly of the V1 and V0 complexes at the vacuole, and possibly
in assembly at the early endosome. Modified from (9).
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This supplements the previous view that azoles cause
fungal toxicity through damage of the cell membrane
followed by increased cell permeability and lysis (12).
Loss of V-ATPase function
Experiments with S. cerevisiae have demonstrated that
loss of ATPase function causes a number of growth
defects referred to as the vma phenotype (5, 11). This
phenotype does not grow on media that are alkaline (pH
7.58.5) and contains high concentrations of calcium or
non-fermentable carbon sources as the sole carbon
source (9). However, growth on acid media (pH 4.0
5.0) is similar to that of the wild type and similar findings
have been obtained with C. albicans. By creating a
conditional mutant controlled by a tetracycline-regulated
promoter (tetR-VMA3 strain), repression of VMA3 in
the tet-VMA3 strain prevented V-ATPase assembly at the
vacuolar membrane. It also reduced concanamycin A
(ATPase inhibitor)-sensitive ATPase-specific activity and
proton transport by90% (5). Later, several other
examples will be given on how interference with ATPase
function can have serious consequences for the virulence
of C. albicans.
Interference with extracellular pH
C. albicans has a broad tolerance spectrum for pH since it
survives in ecological niches fromhighly acidic pH (B2) to
alkaline pH (10) (13, 14). The extracellular pH affects
dimorphism of C. albicans with the yeast form promoted
under acidic conditions and the filament form (patho-
genic) under alkaline conditions. This means that in-
creased extracellular pH can increase the virulence
through filament production by the yeast (15). C. albicans
can actively change the pH of the environment and in-
duce hyphae formation. Mutants showing reduced ability
to sense extracellular pH have reduced virulence (16).
Interference with vacuolar pH
The yeast vacuole is a major target for antifungal drugs
preventing it from becoming acidic. Thus, fluconazole is
able to block the yeast-to-hyphal transition (17) and
inhibits V-ATPase by emptying yeast membranes of
ergosterol. This causes alkalization of the vacuole (10,
18). Also, amphotericin B, binding to ergosterol, can
decrease V-ATPase activity (11). As aforementioned, the
azole class of antifungals functions partly by disruption of
vacuolar acidification. Loss of C. albicans V-ATPase
activity causing alkalization of the vacuolar lumen has
several pleiotropic effects affecting pH-dependent growth,
and calcium and cold sensitivity (5). Thus, vacuolar
acidification is clearly linked to the pathogenicity of the
yeast. Another new and interesting target for antifungal
drugs is the putative vacuolar transport protein Vac1p that
is needed for several cellular functions, particularly those
controlling virulence and pathogenicity ofC. albicans (19).
It was shown by Poltermann et al. (20) that the vacuolar
ATPase subunit Vma7p is involved in vacuole acidifi-
cation and is needed for hyphal growth and virulence of
C. albicans. Null mutants of C. albicans, vma7, had
defective proton transport into the vacuole indicated by
an alkaline pH. The alkaline vesicular lumen may disturb
degradation of intravacuolar structures by its hydrolases
and lipases. No hyphal growth was seen by the vma7 null
mutant in liquid medium. Vma7p interacts physically with
the PI 3-kinase Vps34p, which is a key enzyme in vacuolar
protein transport. Poltermann et al. (20) also showed that
their respective null mutants, vma7 and vps34, had the
same defects invacuolar acidification and detoxification of
metal ions, linking vacuolar proton transport and vacuole
acidification with vacuolar protein transport.
The story of the yeast vacuole is additionally intriguing
by the fact that fungal V-ATPase, unlike mammalian
orthologs, has little isoform diversity in its structural sub-
units. An exception is theVo subunit a, which is encoded by
the genes VPH1 and STV1 in C. albicans (and S. cere-
visiae). These genes, through their functional properties
and organelle distribution of V-ATPase complexes, har-
boring either Vph1p or Stv1p, enabled Patenaude et al.
(21) to determine the relative contribution of vacuolar and
secretory pathway acidification to pathogenicity and
related traits such as the change in morphology from
blastoconidiae to hyphae. They showed that the vacuole-
specific subunita isoform,Vph1p,was needed for vacuolar
acidification, and that this could not be performed
adequately by the Stv1p isoform. This supported previous
observations by Tarsio et al. (22) who found that loss of
STV1 had little effect on vacuolar pH, while loss of VPH1
caused vacuolar alkalization. The observations were con-
sistent with previous findings in the non-pathogenic yeast
S. cerevisiae (21). When injected into a murine model of
systemic candidosis, the vph1-null strain did not kill any of
the animals during the observation period whereas a
reintegrant of VPH1 in the null strain maintained its
virulence (21). In other words, the yeast that was unable to
achieve vacuolar acidity did not kill the mice.
Raines et al. (23) found that the Vph1p isoform of V-
ATPase controlled V-ATPase activity and acidification of
the vacuole inC. albicans.However, vacuolar acidification
was not essential for filamentation in vitro. They suggested
for the first time a role also for Stv1p-containingV-ATPase
complexes in C. albicans virulence, particularly if Vph1 is
not functional. As a determinant forC. albicans filamenta-
tion, they proposed that vacuolar pH alone may be less
important than previously thought, at least in vitro, and
that bothVph1p- and Stv1p-containingV-ATPasemust be
inhibited to prevent C. albicans infection. The disparate
results of Patenaude et al. (21) andRaines et al. (23)may be
related to differences in test strains and methodology.
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However, they both suggested that ATPase activity could
be used to control C. albicans virulence.
Drug synergy in antifungal treatment
It has been mentioned that there is a critical requirement
for ergosterol in V-ATPase function, and that this require-
ment may actually underlie the antifungal effect of azoles
(11). Interestingly, combinations of azole drugs with non-
antifungals can trigger harmful ion fluxes that can have
synergistic antifungal effects. Amiodarone is a drug used
therapeutically and prophylactically against serious heart
arrhythmia. It causes a surge of cytosolic H and Ca2 ,
and elicits stress, cell-cycle arrest and fungal death (18, 24,
25). Combining amiodaronewith fluconazole significantly
dampened the transcriptional response to either drug
which indicated that the synergism was caused by inhibi-
tion of compensatory response pathways (11, 26, 27).
Dampening was associated with a decrease in total
ergosterol levels and reduced the formation of pseudohy-
phae. In a mouse model of systemic candidosis, the
combination of amiodarone with azole was effective in
the treatment of the fungal infection (11). Synergy has also
been demonstrated between amphotericin B and allicin,
the main active component in freshly crushed garlic
extract, enhancing the effects of vacuole-targeting fungi-
cidal activity of amphotericin B (28). Interestingly, there is
also a considerable potential for azoles used together with
amiodarone against resistant C. albicans (27). These
findings point to the possibilityof allotting new indications
to already existing drugs, which may be far less expensive
than designing entirely new antifungal drugs. Also, target-
ing components of the V-ATPase pathway via a down-
stream element such as Pma1p (fungal-specific protein
with no knownmammalian homologs) can circumvent the
development of drug resistance against current antifungal
therapies (29). Anti-Pma1p drugs may also act against
yeasts without required drug accumulation within the
fungal cell since Pma1p, being a plasma membrane
protein, has access to the extracellular space (29).
Anti-V-ATPase drugs
Anti-V-ATPase drugs may be effective in the treatment of
candidosis (29). By 2009, eight types of V-ATPase in-
hibitors had been described (30). Among them were natu-
rally occurring compounds that inhibit V-ATPase such as
specific and potent inhibitors produced by Streptomyces
species: bafilomycin A1 and concanamycin A (30, 31).
Unfortunately, these compounds are unable to discrimi-
nate between fungal and mammalian V-ATPase (32, 33).
In a screening of two compound libraries, the ENZO and
the FIMM oncology collection library for anti-Candida
activity, Stylianou et al. (34) found seven off-target drugs
previously reported to be active against Candida species
and seven new agents (amonafide, tosedostat, megestrol
acetate, melengestrol acetate, stanozolol, trifluperidol,
and haloperidol) with anti-Candida activity. The amino-
peptidase inhibitor tosedostat, which is being clinically
trialled for anti-cancer therapy, had a broad antifungal
activity against different Candida species, including C.
glabrata.
Chan et al. (35) used the pHluorin screening method
on the Prestwick Chemical Library containing 1,120 off-
patent drugs and identified alexidine dihydrochloride and
thonzonium bromide as new and specific ATPase in-
hibitors. They also confirmed disulfiram as an inhibitor
of V-ATPase in C. albicans. Noteworthy, most drugs in
the Prestwick Chemical Library had known safety and
toxicity profiles. In addition, alexidine dihydrochloride
and thonzonium bromide showed general toxicity to
C. albicans cells. Therefore, anti-V-ATPase drugs may
be used clinically. Most importantly, they may evade the
problem of multiresistance experienced with azoles.
Interference with filament production
Interference with the V-ATPase function can also disable
the capacity of the yeast to produce filaments. Many
authors consider filaments as the pathogenic form of the
organism.Thiswas demonstratedwith the vma7-1- strain of
C. albicans in serum or liquid Spider medium with
mannitol (20). Normally, hyphal growth is induced under
these growth conditions. This was not the case with the
vma7 null mutant, which was also avirulent in a mouse
model of systemic candidosis (20). Treatment with fluco-
nazole and ERG3 deletion also inhibited filamentation in
C. albicans (17, 36). When a wild-type ERG3 allele was
reintroduced into a homozygous deletion mutant of
C. albicans, virulence, ergosterol synthesis, and suscept-
ibility to azoles were restored. It was concluded that the
loss of virulence was most likely due to the erg3 mutant’s
failing ability to form hyphae. Recently, Rane et al. (5)
found that repression of VMA3, which is a gene that
encodes the c subunit of the V0 subcomplex, suppressed
filamentation in C. albicans. Specific chemical inhibition
of Vma3p function also reduced filament production.
There were also fission defects causing reduced protease
and lipase secretion and ineffectivemacrophage killing (5).
Furthermore, damage to the host and lethality were shown
to be associatedwith active invasive filamentous growth in
mice injected with C. albicans into the tail vein (37).
Therefore, inhibition of filamentation was suggested as a
method for treatment of disseminated candidosis.
Host cell toxicity and drug resistance
As mentioned, there are naturally occurring compounds
that inhibit V-ATPase such as specific and potent
inhibitors produced by Streptomyces species: bafilomycin
A1 and concanamycin A (31, 32). Unfortunately, these
compounds are unable to discriminate between fungal
and mammalian V-ATPase (30, 33).
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More promising is the fungus-specific V-ATPase sub-
unit c?, which is encoded by VMA11 and has no mamma-
lian homolog (5). The combination of antifungals with
non-antifungal drugs is also promising in terms of toxicity.
By achieving synergy, the doses of each drug may be
reduced so that they can be tolerated by the host. As
previously mentioned, drug synergy is a principle that also
can be useful against antifungal drug resistance (27).
A prerequisite for all the approaches to reduce C.
albicans virulence in man is that they have been tested for
host cell toxicity and have been shown to be without
major side effects. Until this has been done, they cannot
be used for reducing morbidity and mortality even in
seriously ill patients. Fortunately, targeting pathogen-
specific factors may allow a very specific action on
Candida and enable reduced incidence of resistance
(38). Interestingly, low levels of azoles did not affect
C. albicans growth in vitro but inhibited extensive hyphal
elongation (39) suggesting another therapeutic option
that could be well tolerated by patients.
Conclusions
In conclusion, we may impair C. albicans virulence
through affecting functions of its vacuole. The vacuole
has an essential role in supporting yeast pathogenicity by
performing a variety of important functions during
colonization and invasion of the host. Impairment can
theoretically be done by inhibiting V-ATPase functions
and acidification of the vacuole, by seeking the synergis-
tic effect of antifungals together with non-antifungals, by
applying V-ATPase inhibitors, and by inhibiting filament
production, also guided by the vacuole.
Except for drugs where indications for clinical use can
be redefined, some of these approaches may be closer to
theory than to reality. However, since the yeast is so
difficult to eradicate by antifungal treatment, it may be
more rewarding to seek new strategies for reducing its
virulence than trying to wipe it out of the entire microbial
population. This often turns out to be impossible.
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